伊布替尼
医学
苯达莫司汀
美罗华
内科学
套细胞淋巴瘤
癌症研究
肿瘤科
淋巴瘤
白血病
慢性淋巴细胞白血病
作者
Michael Wang,Wojciech Jurczak,Mats Jerkeman,Judith Trotman,Pier Luigi Zinzani,David Belada,Carola Boccomini,Ian W. Flinn,Pratyush Giri,André Goy,Paul A. Hamlin,Olivier Hermine,José‐Ángel Hernández‐Rivas,Xiaonan Hong,Seok Jin Kim,David John Lewis,Yuko Mishima,Muhıt Özcan,Guilherme Fleury Perini,Christopher Pocock
标识
DOI:10.1056/nejmoa2201817
摘要
Ibrutinib, a Bruton's tyrosine kinase inhibitor, may have clinical benefit when administered in combination with bendamustine and rituximab and followed by rituximab maintenance therapy in older patients with untreated mantle-cell lymphoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI